Last reviewed · How we verify
NCT03858361: PSOT
Patient Specific Optimized Therapy (PSOT)
trial testing Atrial Flutter Ablation in Data Collection in 566 participants. Terminated before completion.
28 March 2023
Quick facts
| Lead sponsor | EPD Solutions, A Philips Company |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 566 |
| Start date | 13 September 2019 |
| Primary completion | 28 March 2023 |
| Estimated completion | 28 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Atrial Flutter Ablation
Conditions studied
- Data Collection — all drugs for Data Collection →
Sponsor
EPD Solutions, A Philips Company
Who can join
18 and older, any sex, with Data Collection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Data collection from atrial flutter patients before, during and after undergoing catheter-based electrophysiological (EP) intervention in order to develop a patient specific optimized therapy (PSOT) to improve specific patient's arrhythmia treatment for Atrial Flutter.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03858361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Data Collection
Currently open trials in the same condition.
- NCT07371559 — Assessment of Food Intake Using Both 3D Scanning Method and a Photographic Method · recruiting
Other EPD Solutions, A Philips Company trials
Trials by the same sponsor.
- NCT04293198 — Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation · completed
- NCT04552665 — Prospective Procedural Data Collection for Continuous Improvement of the KODEX - EPD™ System Performance. · terminated
- NCT04438395 — Dielectric Tissue Imaging in Cavotricuspid Isthmus Ablation · unknown
- NCT03481413 — Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study · terminated
- NCT02878213 — DURABLE-I Study: Dielectric Unravelling of Radiofrequency ABLation Effectiveness · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03858361 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EPD Solutions, A Philips Company
- Last refreshed: 8 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03858361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing